The global market for Multiple Myeloma Drugs was estimated to be worth US$ 874 million in 2023 and is forecast to a readjusted size of US$ 1271.1 million by 2030 with a CAGR of 6.2% during the forecast period 2024-2030

Multiple Myeloma Drugs - Market

Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Multiple Myeloma Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Multiple Myeloma Drugs by region & country, by Type, and by Application.

The Multiple Myeloma Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Myeloma Drugs.

Market Segmentation

Scope of Multiple Myeloma Drugs - Market Report

Report Metric	Details
Report Name	Multiple Myeloma Drugs - Market
Forecasted market size in 2030	US$ 1271.1 million
CAGR	6.2%
Forecasted years	2024 - 2030
Segment by Type:	Chemotherapy Corticosteroids Immunomodulators Monoclonal Antibodies Histone Deacetylase (HDAC) Inhibitors Proteasome Inhibitors Others
Segment by Application	Men Women
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Amgen, Johnson & Johnson, Celgene, Takeda Pharmaceutical, Novartis, Daiichi Sankyo, Merck, AB Science, Teva, PharmaMar
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Multiple Myeloma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Multiple Myeloma Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Multiple Myeloma Drugs - Market size in 2030?

Ans: The Multiple Myeloma Drugs - Market size in 2030 will be US$ 1271.1 million.

Who are the main players in the Multiple Myeloma Drugs - Market report?

Ans: The main players in the Multiple Myeloma Drugs - Market are Amgen, Johnson & Johnson, Celgene, Takeda Pharmaceutical, Novartis, Daiichi Sankyo, Merck, AB Science, Teva, PharmaMar

What are the Application segmentation covered in the Multiple Myeloma Drugs - Market report?

Ans: The Applications covered in the Multiple Myeloma Drugs - Market report are Men, Women

What are the Type segmentation covered in the Multiple Myeloma Drugs - Market report?

Ans: The Types covered in the Multiple Myeloma Drugs - Market report are Chemotherapy, Corticosteroids, Immunomodulators, Monoclonal Antibodies, Histone Deacetylase (HDAC) Inhibitors, Proteasome Inhibitors, Others

1 Market Overview

1.1 Multiple Myeloma Drugs Product Introduction

1.2 Global Multiple Myeloma Drugs Market Size Forecast

1.2.1 Global Multiple Myeloma Drugs Sales Value (2019-2030)

1.2.2 Global Multiple Myeloma Drugs Sales Volume (2019-2030)

1.2.3 Global Multiple Myeloma Drugs Sales Price (2019-2030)

1.3 Multiple Myeloma Drugs Market Trends & Drivers

1.3.1 Multiple Myeloma Drugs Industry Trends

1.3.2 Multiple Myeloma Drugs Market Drivers & Opportunity

1.3.3 Multiple Myeloma Drugs Market Challenges

1.3.4 Multiple Myeloma Drugs Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Multiple Myeloma Drugs Players Revenue Ranking (2023)

2.2 Global Multiple Myeloma Drugs Revenue by Company (2019-2024)

2.3 Global Multiple Myeloma Drugs Players Sales Volume Ranking (2023)

2.4 Global Multiple Myeloma Drugs Sales Volume by Company Players (2019-2024)

2.5 Global Multiple Myeloma Drugs Average Price by Company (2019-2024)

2.6 Key Manufacturers Multiple Myeloma Drugs Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Multiple Myeloma Drugs Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Multiple Myeloma Drugs

2.9 Multiple Myeloma Drugs Market Competitive Analysis

2.9.1 Multiple Myeloma Drugs Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Multiple Myeloma Drugs Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Myeloma Drugs as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Chemotherapy

3.1.2 Corticosteroids

3.1.3 Immunomodulators

3.1.4 Monoclonal Antibodies

3.1.5 Histone Deacetylase (HDAC) Inhibitors

3.1.6 Proteasome Inhibitors

3.1.7 Others

3.2 Global Multiple Myeloma Drugs Sales Value by Type

3.2.1 Global Multiple Myeloma Drugs Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Multiple Myeloma Drugs Sales Value, by Type (2019-2030)

3.2.3 Global Multiple Myeloma Drugs Sales Value, by Type (%) (2019-2030)

3.3 Global Multiple Myeloma Drugs Sales Volume by Type

3.3.1 Global Multiple Myeloma Drugs Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Multiple Myeloma Drugs Sales Volume, by Type (2019-2030)

3.3.3 Global Multiple Myeloma Drugs Sales Volume, by Type (%) (2019-2030)

3.4 Global Multiple Myeloma Drugs Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Men

4.1.2 Women

4.2 Global Multiple Myeloma Drugs Sales Value by Application

4.2.1 Global Multiple Myeloma Drugs Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Multiple Myeloma Drugs Sales Value, by Application (2019-2030)

4.2.3 Global Multiple Myeloma Drugs Sales Value, by Application (%) (2019-2030)

4.3 Global Multiple Myeloma Drugs Sales Volume by Application

4.3.1 Global Multiple Myeloma Drugs Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Multiple Myeloma Drugs Sales Volume, by Application (2019-2030)

4.3.3 Global Multiple Myeloma Drugs Sales Volume, by Application (%) (2019-2030)

4.4 Global Multiple Myeloma Drugs Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Multiple Myeloma Drugs Sales Value by Region

5.1.1 Global Multiple Myeloma Drugs Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Multiple Myeloma Drugs Sales Value by Region (2019-2024)

5.1.3 Global Multiple Myeloma Drugs Sales Value by Region (2025-2030)

5.1.4 Global Multiple Myeloma Drugs Sales Value by Region (%), (2019-2030)

5.2 Global Multiple Myeloma Drugs Sales Volume by Region

5.2.1 Global Multiple Myeloma Drugs Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Multiple Myeloma Drugs Sales Volume by Region (2019-2024)

5.2.3 Global Multiple Myeloma Drugs Sales Volume by Region (2025-2030)

5.2.4 Global Multiple Myeloma Drugs Sales Volume by Region (%), (2019-2030)

5.3 Global Multiple Myeloma Drugs Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Multiple Myeloma Drugs Sales Value, 2019-2030

5.4.2 North America Multiple Myeloma Drugs Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Multiple Myeloma Drugs Sales Value, 2019-2030

5.5.2 Europe Multiple Myeloma Drugs Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Multiple Myeloma Drugs Sales Value, 2019-2030

5.6.2 Asia Pacific Multiple Myeloma Drugs Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Multiple Myeloma Drugs Sales Value, 2019-2030

5.7.2 South America Multiple Myeloma Drugs Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Multiple Myeloma Drugs Sales Value, 2019-2030

5.8.2 Middle East & Africa Multiple Myeloma Drugs Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Multiple Myeloma Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Multiple Myeloma Drugs Sales Value

6.2.1 Key Countries/Regions Multiple Myeloma Drugs Sales Value, 2019-2030

6.2.2 Key Countries/Regions Multiple Myeloma Drugs Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Multiple Myeloma Drugs Sales Value, 2019-2030

6.3.2 United States Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Multiple Myeloma Drugs Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Multiple Myeloma Drugs Sales Value, 2019-2030

6.4.2 Europe Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Multiple Myeloma Drugs Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Multiple Myeloma Drugs Sales Value, 2019-2030

6.5.2 China Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

6.5.3 China Multiple Myeloma Drugs Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Multiple Myeloma Drugs Sales Value, 2019-2030

6.6.2 Japan Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Multiple Myeloma Drugs Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Multiple Myeloma Drugs Sales Value, 2019-2030

6.7.2 South Korea Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Multiple Myeloma Drugs Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Multiple Myeloma Drugs Sales Value, 2019-2030

6.8.2 Southeast Asia Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Multiple Myeloma Drugs Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Multiple Myeloma Drugs Sales Value, 2019-2030

6.9.2 India Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

6.9.3 India Multiple Myeloma Drugs Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Amgen

7.1.1 Amgen Company Information

7.1.2 Amgen Introduction and Business Overview

7.1.3 Amgen Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Amgen Multiple Myeloma Drugs Product Offerings

7.1.5 Amgen Recent Development

7.2 Johnson & Johnson

7.2.1 Johnson & Johnson Company Information

7.2.2 Johnson & Johnson Introduction and Business Overview

7.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)

7.2.4 Johnson & Johnson Multiple Myeloma Drugs Product Offerings

7.2.5 Johnson & Johnson Recent Development

7.3 Celgene

7.3.1 Celgene Company Information

7.3.2 Celgene Introduction and Business Overview

7.3.3 Celgene Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Celgene Multiple Myeloma Drugs Product Offerings

7.3.5 Celgene Recent Development

7.4 Takeda Pharmaceutical

7.4.1 Takeda Pharmaceutical Company Information

7.4.2 Takeda Pharmaceutical Introduction and Business Overview

7.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Takeda Pharmaceutical Multiple Myeloma Drugs Product Offerings

7.4.5 Takeda Pharmaceutical Recent Development

7.5 Novartis

7.5.1 Novartis Company Information

7.5.2 Novartis Introduction and Business Overview

7.5.3 Novartis Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Novartis Multiple Myeloma Drugs Product Offerings

7.5.5 Novartis Recent Development

7.6 Daiichi Sankyo

7.6.1 Daiichi Sankyo Company Information

7.6.2 Daiichi Sankyo Introduction and Business Overview

7.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Daiichi Sankyo Multiple Myeloma Drugs Product Offerings

7.6.5 Daiichi Sankyo Recent Development

7.7 Merck

7.7.1 Merck Company Information

7.7.2 Merck Introduction and Business Overview

7.7.3 Merck Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Merck Multiple Myeloma Drugs Product Offerings

7.7.5 Merck Recent Development

7.8 AB Science

7.8.1 AB Science Company Information

7.8.2 AB Science Introduction and Business Overview

7.8.3 AB Science Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)

7.8.4 AB Science Multiple Myeloma Drugs Product Offerings

7.8.5 AB Science Recent Development

7.9 Teva

7.9.1 Teva Company Information

7.9.2 Teva Introduction and Business Overview

7.9.3 Teva Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Teva Multiple Myeloma Drugs Product Offerings

7.9.5 Teva Recent Development

7.10 PharmaMar

7.10.1 PharmaMar Company Information

7.10.2 PharmaMar Introduction and Business Overview

7.10.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)

7.10.4 PharmaMar Multiple Myeloma Drugs Product Offerings

7.10.5 PharmaMar Recent Development

8 Industry Chain Analysis

8.1 Multiple Myeloma Drugs Industrial Chain

8.2 Multiple Myeloma Drugs Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Multiple Myeloma Drugs Sales Model

8.5.2 Sales Channel

8.5.3 Multiple Myeloma Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Amgen Inc

Johnson & Johnson

Celgene

Takeda Pharmaceutical

List of Tables

Table 1. Multiple Myeloma Drugs Market Trends

Table 2. Multiple Myeloma Drugs Market Drivers & Opportunity

Table 3. Multiple Myeloma Drugs Market Challenges

Table 4. Multiple Myeloma Drugs Market Restraints

Table 5. Global Multiple Myeloma Drugs Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Multiple Myeloma Drugs Revenue Market Share by Company (2019-2024)

Table 7. Global Multiple Myeloma Drugs Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Multiple Myeloma Drugs Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Multiple Myeloma Drugs Price by Company (2019-2024) & (USD/Unit)

Table 10. Key Manufacturers Multiple Myeloma Drugs Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Multiple Myeloma Drugs Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Multiple Myeloma Drugs

Table 13. Global Multiple Myeloma Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Myeloma Drugs as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Multiple Myeloma Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Multiple Myeloma Drugs Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Multiple Myeloma Drugs Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Multiple Myeloma Drugs Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Multiple Myeloma Drugs Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Multiple Myeloma Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Multiple Myeloma Drugs Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Multiple Myeloma Drugs Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Multiple Myeloma Drugs Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Multiple Myeloma Drugs Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Multiple Myeloma Drugs Price by Type (2019-2024) & (USD/Unit)

Table 27. Global Multiple Myeloma Drugs Price by Type (2025-2030) & (USD/Unit)

Table 28. Global Multiple Myeloma Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Multiple Myeloma Drugs Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Multiple Myeloma Drugs Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Multiple Myeloma Drugs Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Multiple Myeloma Drugs Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Multiple Myeloma Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Multiple Myeloma Drugs Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Multiple Myeloma Drugs Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Multiple Myeloma Drugs Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Multiple Myeloma Drugs Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Multiple Myeloma Drugs Price by Application (2019-2024) & (USD/Unit)

Table 39. Global Multiple Myeloma Drugs Price by Application (2025-2030) & (USD/Unit)

Table 40. Global Multiple Myeloma Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Multiple Myeloma Drugs Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Multiple Myeloma Drugs Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Multiple Myeloma Drugs Sales Value by Region (2019-2024) & (%)

Table 44. Global Multiple Myeloma Drugs Sales Value by Region (2025-2030) & (%)

Table 45. Global Multiple Myeloma Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Multiple Myeloma Drugs Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Multiple Myeloma Drugs Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Multiple Myeloma Drugs Sales Volume by Region (2019-2024) & (%)

Table 49. Global Multiple Myeloma Drugs Sales Volume by Region (2025-2030) & (%)

Table 50. Global Multiple Myeloma Drugs Average Price by Region (2019-2024) & (USD/Unit)

Table 51. Global Multiple Myeloma Drugs Average Price by Region (2025-2030) & (USD/Unit)

Table 52. Key Countries/Regions Multiple Myeloma Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Multiple Myeloma Drugs Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Multiple Myeloma Drugs Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Multiple Myeloma Drugs Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Multiple Myeloma Drugs Sales Volume, (2025-2030) & (K Units)

Table 57. Amgen Company Information

Table 58. Amgen Introduction and Business Overview

Table 59. Amgen Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 60. Amgen Multiple Myeloma Drugs Product Offerings

Table 61. Amgen Recent Development

Table 62. Johnson & Johnson Company Information

Table 63. Johnson & Johnson Introduction and Business Overview

Table 64. Johnson & Johnson Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 65. Johnson & Johnson Multiple Myeloma Drugs Product Offerings

Table 66. Johnson & Johnson Recent Development

Table 67. Celgene Company Information

Table 68. Celgene Introduction and Business Overview

Table 69. Celgene Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 70. Celgene Multiple Myeloma Drugs Product Offerings

Table 71. Celgene Recent Development

Table 72. Takeda Pharmaceutical Company Information

Table 73. Takeda Pharmaceutical Introduction and Business Overview

Table 74. Takeda Pharmaceutical Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 75. Takeda Pharmaceutical Multiple Myeloma Drugs Product Offerings

Table 76. Takeda Pharmaceutical Recent Development

Table 77. Novartis Company Information

Table 78. Novartis Introduction and Business Overview

Table 79. Novartis Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 80. Novartis Multiple Myeloma Drugs Product Offerings

Table 81. Novartis Recent Development

Table 82. Daiichi Sankyo Company Information

Table 83. Daiichi Sankyo Introduction and Business Overview

Table 84. Daiichi Sankyo Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 85. Daiichi Sankyo Multiple Myeloma Drugs Product Offerings

Table 86. Daiichi Sankyo Recent Development

Table 87. Merck Company Information

Table 88. Merck Introduction and Business Overview

Table 89. Merck Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 90. Merck Multiple Myeloma Drugs Product Offerings

Table 91. Merck Recent Development

Table 92. AB Science Company Information

Table 93. AB Science Introduction and Business Overview

Table 94. AB Science Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 95. AB Science Multiple Myeloma Drugs Product Offerings

Table 96. AB Science Recent Development

Table 97. Teva Company Information

Table 98. Teva Introduction and Business Overview

Table 99. Teva Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 100. Teva Multiple Myeloma Drugs Product Offerings

Table 101. Teva Recent Development

Table 102. PharmaMar Company Information

Table 103. PharmaMar Introduction and Business Overview

Table 104. PharmaMar Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 105. PharmaMar Multiple Myeloma Drugs Product Offerings

Table 106. PharmaMar Recent Development

Table 107. Key Raw Materials Lists

Table 108. Raw Materials Key Suppliers Lists

Table 109. Multiple Myeloma Drugs Downstream Customers

Table 110. Multiple Myeloma Drugs Distributors List

Table 111. Research Programs/Design for This Report

Table 112. Key Data Information from Secondary Sources

Table 113. Key Data Information from Primary Sources

List of Figures

Figure 1. Multiple Myeloma Drugs Product Picture

Figure 2. Global Multiple Myeloma Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Multiple Myeloma Drugs Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Multiple Myeloma Drugs Sales Volume (2019-2030) & (K Units)

Figure 5. Global Multiple Myeloma Drugs Sales Price (2019-2030) & (USD/Unit)

Figure 6. Multiple Myeloma Drugs Report Years Considered

Figure 7. Global Multiple Myeloma Drugs Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Multiple Myeloma Drugs Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Multiple Myeloma Drugs Revenue in 2023

Figure 10. Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Chemotherapy Picture

Figure 12. Corticosteroids Picture

Figure 13. Immunomodulators Picture

Figure 14. Monoclonal Antibodies Picture

Figure 15. Histone Deacetylase (HDAC) Inhibitors Picture

Figure 16. Proteasome Inhibitors Picture

Figure 17. Others Picture

Figure 18. Global Multiple Myeloma Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global Multiple Myeloma Drugs Sales Value Market Share by Type, 2023 & 2030

Figure 20. Global Multiple Myeloma Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 21. Global Multiple Myeloma Drugs Sales Volume Market Share by Type, 2023 & 2030

Figure 22. Global Multiple Myeloma Drugs Price by Type (2019-2030) & (USD/Unit)

Figure 23. Product Picture of Men

Figure 24. Product Picture of Women

Figure 25. Global Multiple Myeloma Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 26. Global Multiple Myeloma Drugs Sales Value Market Share by Application, 2023 & 2030

Figure 27. Global Multiple Myeloma Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 28. Global Multiple Myeloma Drugs Sales Volume Market Share by Application, 2023 & 2030

Figure 29. Global Multiple Myeloma Drugs Price by Application (2019-2030) & (USD/Unit)

Figure 30. North America Multiple Myeloma Drugs Sales Value (2019-2030) & (US$ Million)

Figure 31. North America Multiple Myeloma Drugs Sales Value by Country (%), 2023 VS 2030

Figure 32. Europe Multiple Myeloma Drugs Sales Value (2019-2030) & (US$ Million)

Figure 33. Europe Multiple Myeloma Drugs Sales Value by Country (%), 2023 VS 2030

Figure 34. Asia Pacific Multiple Myeloma Drugs Sales Value (2019-2030) & (US$ Million)

Figure 35. Asia Pacific Multiple Myeloma Drugs Sales Value by Country (%), 2023 VS 2030

Figure 36. South America Multiple Myeloma Drugs Sales Value (2019-2030) & (US$ Million)

Figure 37. South America Multiple Myeloma Drugs Sales Value by Country (%), 2023 VS 2030

Figure 38. Middle East & Africa Multiple Myeloma Drugs Sales Value (2019-2030) & (US$ Million)

Figure 39. Middle East & Africa Multiple Myeloma Drugs Sales Value by Country (%), 2023 VS 2030

Figure 40. Key Countries/Regions Multiple Myeloma Drugs Sales Value (%), (2019-2030)

Figure 41. Key Countries/Regions Multiple Myeloma Drugs Sales Volume (%), (2019-2030)

Figure 42. United States Multiple Myeloma Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 43. United States Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

Figure 44. United States Multiple Myeloma Drugs Sales Value by Application (%), 2023 VS 2030

Figure 45. Europe Multiple Myeloma Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 46. Europe Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

Figure 47. Europe Multiple Myeloma Drugs Sales Value by Application (%), 2023 VS 2030

Figure 48. China Multiple Myeloma Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 49. China Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

Figure 50. China Multiple Myeloma Drugs Sales Value by Application (%), 2023 VS 2030

Figure 51. Japan Multiple Myeloma Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 52. Japan Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

Figure 53. Japan Multiple Myeloma Drugs Sales Value by Application (%), 2023 VS 2030

Figure 54. South Korea Multiple Myeloma Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 55. South Korea Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

Figure 56. South Korea Multiple Myeloma Drugs Sales Value by Application (%), 2023 VS 2030

Figure 57. Southeast Asia Multiple Myeloma Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 58. Southeast Asia Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

Figure 59. Southeast Asia Multiple Myeloma Drugs Sales Value by Application (%), 2023 VS 2030

Figure 60. India Multiple Myeloma Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 61. India Multiple Myeloma Drugs Sales Value by Type (%), 2023 VS 2030

Figure 62. India Multiple Myeloma Drugs Sales Value by Application (%), 2023 VS 2030

Figure 63. Multiple Myeloma Drugs Industrial Chain

Figure 64. Multiple Myeloma Drugs Manufacturing Cost Structure

Figure 65. Channels of Distribution (Direct Sales, and Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-6T7647

Tue Oct 08 00:00:00 UTC 2024

Add to Cart

Anti-Oral Mucositis Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-5V5924

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Transarterial Chemoembolization (TACE) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-18Y13983

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Multiple Myeloma Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-37R6886

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Multiple Myeloma Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: October 2024

Report Code: QYRE-Auto-37R6886

Multiple Myeloma Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

FEATURED COMPANIES

Multiple Myeloma Drugs - Market Size

Multiple Myeloma Drugs - Market

Report Scope

Scope of Multiple Myeloma Drugs - Market Report

Chapter Outline

FAQ for this report

What is the Multiple Myeloma Drugs - Market size in 2030?

Who are the main players in the Multiple Myeloma Drugs - Market report?

What are the Application segmentation covered in the Multiple Myeloma Drugs - Market report?

What are the Type segmentation covered in the Multiple Myeloma Drugs - Market report?

FEATURED COMPANIES

RELATED REPORTS